8-K filed Sep 2, 2026 at 07:22 ET
TScan Therapeutics announced a drastic strategic reorganization: a 75% workforce reduction, termination of its CFO and CMO, and a pause on its lead heme malignancy program (Phase 3 ALLOHA-2) due to capital constraints. The company will focus on early-stage in vivo solid tumor candidates (PRAME and MAGE-A4) and expects cumulative cost savings of $55M through 2027, extending cash runway into Q4 2027. Simultaneously, it received a Nasdaq minimum bid price deficiency notice, creating delisting risk. The combination of severe restructuring, executive departures, and delisting notice signals acute financial distress.